Navigation Links
AstraZeneca Submits sNDAs for SEROQUEL XR(TM) for the Treatment of Bipolar Mania and Bipolar Depression
Date:1/3/2008

a should have their complete blood count monitored frequently during the first few months of therapy. In these patients, SEROQUEL and SEROQUEL XR should be discontinued at the first sign of a decline in WBC absent other causative factors. Patients with neutropenia should be carefully monitored, and SEROQUEL and SEROQUEL XR should be discontinued in any patient if the absolute neutrophil count is < 1000/mm.

Warnings and Precautions also include the risk of orthostatic hypotension, cataracts, seizures and hyperlipidemia. Examination of the lens by methods adequate to detect cataract formation, such as slit lamp exam or other appropriately sensitive methods, is recommended at initiation of treatment, or shortly thereafter, and at 6-month intervals during chronic treatment.

The most commonly observed adverse events associated with the use of SEROQUEL monotherapy versus placebo in clinical trials for schizophrenia and bipolar disorder were dry mouth (9%-44% vs 3%-13%), sedation (30% vs 8%), somnolence (18%-28% vs 7%-8%), dizziness (11%-18% vs 5%-7%), constipation (8%- 10% vs 3%-4%), SGPT increase (5% vs 1%), dyspepsia (5%-7% vs 1%-4%), lethargy (5% vs 2%), and weight gain (5% vs 1%). The most commonly observed adverse events associated with the use of SEROQUEL versus placebo in clinical trials as adjunct therapy with lithium or divalproex in bipolar mania were somnolence (34% vs 9%), dry mouth (19% vs 3%), asthenia (10% vs 4%), constipation (10% vs 5%), abdominal pain (7% vs 3%), postural hypotension (7% vs 2%), pharyngitis (6% vs 3%), and weight gain (6% vs 3%). The most commonly observed adverse events associated with the use of SEROQUEL XR versus placebo in clinical trials for schizophrenia were dry mouth (12% vs 1%), constipation (6% vs 5%), dyspepsia (5% vs 2%), sedation (13% vs 7%), somnolence (12% vs 4%), dizziness (10% vs 4%), and orthostatic hypotension (7% vs 5%).

In long-term clinical trials of quetiapine, hyperglycemia (fasting glucose gr
'/>"/>

SOURCE AstraZeneca
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Abbott and AstraZeneca Announce Selection of Next-Generation Fenofibrate ABT-335 and CRESTOR(R) Fixed-Dose Combination
2. New Analysis of METEOR Study Demonstrate Effects of AstraZenecas CRESTOR(R) (Rosuvastatin Calcium) on Atherosclerosis in Patients With Two or More Risk Factors for Cardiovascular Disease
3. AstraZeneca Completes Enrollment in First Phase III Study of the Investigational Drug Vandetanib (ZACTIMA)(R) in Non-Small Cell Lung Cancer
4. BioMarin Partner AnGes MG, Inc. Submits BLA to Japanese Ministry of Health
5. Peregrine Pharmaceuticals Submits Clinical Protocol to Initiate Bavituximab Phase II Trial in Patients With Metastatic Breast Cancer
6. Vanda Pharmaceuticals Submits Iloperidone New Drug Application
7. Peregrine Pharmaceuticals Submits Clinical Protocol for New Phase II Trial of Bavituximab in Patients With Metastatic Breast Cancer
8. Roche Submits Application for FDA Approval of ACTEMRA(R) for the Treatment of Rheumatoid Arthritis
9. INVEGA(TM) Significantly Reduced Symptoms of Schizophrenia Compared to SEROQUEL(R) in Acutely Ill, Hospitalized Patients
10. SEROQUEL XR(TM) Receives Approval From FDA for Maintenance Treatment of Schizophrenia
11. UCB Announces Positive Phase III Trial Results for Keppra XR(TM) (levetiracetam) Extended-Release Tablets
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/22/2015)...  BiOptix is pleased to announce the appointment of Dr. ... and Biochemistry. Scott joins the company after previous scientific leadership ... the course of his nearly 20 year career in ... nationally recognized thought leader in the biosensor field and ...
(Date:1/22/2015)... RMD ) today announced results for its quarter ... million, a 10 percent increase compared to the quarter ended ... currency basis). Net income was $91.2 million, an increase of ... Diluted earnings per share for the quarter were $0.64, an ...
(Date:1/22/2015)... Calif. , Jan. 22, 2015  Amgen (NASDAQ: AMGN ... full year 2014 financial results on Tuesday, Jan. 27, 2015, after ... followed by a conference call with the investment community at 2 ... Robert A. Bradway , chairman and chief executive officer, and other ...
Breaking Medicine Technology:BiOptix Expands Leadership Team with the Appointment of Dr. Scott Klakamp as Vice President of Chemistry and Biochemistry 2ResMed Inc. Announces Results for the Second Quarter of Fiscal Year 2015 2ResMed Inc. Announces Results for the Second Quarter of Fiscal Year 2015 3ResMed Inc. Announces Results for the Second Quarter of Fiscal Year 2015 4ResMed Inc. Announces Results for the Second Quarter of Fiscal Year 2015 5ResMed Inc. Announces Results for the Second Quarter of Fiscal Year 2015 6ResMed Inc. Announces Results for the Second Quarter of Fiscal Year 2015 7ResMed Inc. Announces Results for the Second Quarter of Fiscal Year 2015 8ResMed Inc. Announces Results for the Second Quarter of Fiscal Year 2015 9ResMed Inc. Announces Results for the Second Quarter of Fiscal Year 2015 10ResMed Inc. Announces Results for the Second Quarter of Fiscal Year 2015 11Amgen Announces Webcast of 2014 Fourth Quarter and Full Year Financial Results 2
... Sanofi Pasteur, the vaccines division of the sanofi-aventis ... has been awarded a three-year contract for $56.94 million ... (HHS) to maintain flocks to enable manufacturing pandemic influenza ... The contract supported by the HHS Biomedical Advanced ...
... Abbott Laboratories has agreed to voluntarily withdraw ... market because of clinical trial data indicating an ... U.S. Food and Drug Administration announced today. ... (Logo: http://www.newscom.com/cgi-bin/prnh/20090824/FDALOGO ) "Meridia,s continued ...
Cached Medicine Technology:Sanofi Pasteur and U.S. Department of Health and Human Services Enter Into Agreement for Pandemic Vaccine Preparedness 2Sanofi Pasteur and U.S. Department of Health and Human Services Enter Into Agreement for Pandemic Vaccine Preparedness 3Sanofi Pasteur and U.S. Department of Health and Human Services Enter Into Agreement for Pandemic Vaccine Preparedness 4Abbott Laboratories Agrees to Withdraw Its Obesity Drug Meridia 2
(Date:1/22/2015)... January 22, 2015 The City of West Hollywood ... a.m., to commemorate the 42nd anniversary of the Supreme Court decision ... “It’s been 42 years since the Roe vs. Wade decision and ... as present as ever,” said City of West Hollywood Councilmember Abbe ...
(Date:1/22/2015)... 23, 2015 VogueQueen is a seasoned and ... and many designers are thrilled to have it lead the ... its new collection of prom dresses for the global market. ... the strategic vision and he focuses on continuing the goal ...
(Date:1/22/2015)... AngelWeddingDress, the premier women’s dress supplier, has ... View website of AngelWeddingDress.com to find more ... dresses online for a bridal party. AngelWeddingDress offers a ... them. Its maternity wedding dresses are specially designed for ...
(Date:1/22/2015)... York, New York (PRWEB) January 22, 2015 ... filed after Fresenius Medical Care recalled its GranuFlo and ... federal multidistrict litigation underway in U.S. District Court, District ... Order dated January 20th, the Court has remanded a ...
(Date:1/22/2015)... 22, 2015 Joan Lunden, award-winning American ... at the upcoming 32nd Annual Miami Breast Cancer ... Education Resource®, LLC (PER®) , shares that “a fast-growing, ... undetected if she had not followed up her clean ...
Breaking Medicine News(10 mins):Health News:VogueQueen Unveils New Designs of Prom Dresses for 2015 2Health News:AngelWeddingDress Has Recently Released Its Collection Of 2015 Maternity Wedding Dresses 2Health News:Court Overseeing Federal GranuFlo Lawsuits Remands Louisiana Claim Back to State Court, Bernstein Liebhard LLP Reports 2Health News:Court Overseeing Federal GranuFlo Lawsuits Remands Louisiana Claim Back to State Court, Bernstein Liebhard LLP Reports 3Health News:Court Overseeing Federal GranuFlo Lawsuits Remands Louisiana Claim Back to State Court, Bernstein Liebhard LLP Reports 4Health News:Joan Lunden Reveals Diagnostic Approach That Led To Early Detection;To Keynote 32nd Annual Miami Breast Cancer Conference® 2Health News:Joan Lunden Reveals Diagnostic Approach That Led To Early Detection;To Keynote 32nd Annual Miami Breast Cancer Conference® 3Health News:Joan Lunden Reveals Diagnostic Approach That Led To Early Detection;To Keynote 32nd Annual Miami Breast Cancer Conference® 4Health News:Joan Lunden Reveals Diagnostic Approach That Led To Early Detection;To Keynote 32nd Annual Miami Breast Cancer Conference® 5Health News:Joan Lunden Reveals Diagnostic Approach That Led To Early Detection;To Keynote 32nd Annual Miami Breast Cancer Conference® 6
... Danaher Corporation (NYSE: DHR ... has approved a regular quarterly dividend of $0.03 ... holders of record on June 26, 2009.Danaher Corporation ... Technologies, Industrial Technologies and Tools and Components ( ...
... Fiscal third quarter revenue from continuing operations increased $25 million, or 5%, to $506 million ... , , , Fiscal ... , , , ... , , , ...
... 7 Abaxis, Inc. (Nasdaq: ABAX ), a ... that Don Wood, chief operations officer, will present at the ... on Thursday, May 14, 2009 at 10:00 a.m. ET. The ... York City.Interested investors are invited to listen to a live ...
... STE ) today announced that its Board of ... to $0.11 per common share. The dividend is payable ... of business on May 21, 2009. About STERIS ... healthier today and safer tomorrow through knowledgeable people and innovative ...
... National Organization Dedicated to Advancing the Patient ... The Quantum Group, a healthcare services organization ... the Patient-Centered Primary Care Collaborative (PCPCC). The ... consumer groups, patient quality organizations, health plans, ...
... Worldwide Forensic Casework Revenues Grow Significantly , , ... (Nasdaq: ORCH ), a leading worldwide provider of ... the first quarter of 2009.Total revenues were $14.0 million for ... the first quarter of 2008, despite the adverse impact of ...
Cached Medicine News:Health News:Perrigo Reports Record Third Quarter 2Health News:Perrigo Reports Record Third Quarter 3Health News:Perrigo Reports Record Third Quarter 4Health News:Perrigo Reports Record Third Quarter 5Health News:Perrigo Reports Record Third Quarter 6Health News:Perrigo Reports Record Third Quarter 7Health News:Perrigo Reports Record Third Quarter 8Health News:Perrigo Reports Record Third Quarter 9Health News:Perrigo Reports Record Third Quarter 10Health News:Perrigo Reports Record Third Quarter 11Health News:Perrigo Reports Record Third Quarter 12Health News:Perrigo Reports Record Third Quarter 13Health News:Perrigo Reports Record Third Quarter 14Health News:Perrigo Reports Record Third Quarter 15Health News:Perrigo Reports Record Third Quarter 16Health News:Perrigo Reports Record Third Quarter 17Health News:Perrigo Reports Record Third Quarter 18Health News:Perrigo Reports Record Third Quarter 19Health News:Perrigo Reports Record Third Quarter 20Health News:Perrigo Reports Record Third Quarter 21Health News:Perrigo Reports Record Third Quarter 22Health News:Abaxis, Inc. to Present at Bank of America and Merrill Lynch 2009 Health Care Conference 2Health News:STERIS Corporation Announces Quarterly Dividend Increase of 38% 2Health News:STERIS Corporation Announces Quarterly Dividend Increase of 38% 3Health News:The Quantum Group Joins Executive Committee of the Patient-Centered Primary Care Collaborative 2Health News:The Quantum Group Joins Executive Committee of the Patient-Centered Primary Care Collaborative 3Health News:The Quantum Group Joins Executive Committee of the Patient-Centered Primary Care Collaborative 4Health News:The Quantum Group Joins Executive Committee of the Patient-Centered Primary Care Collaborative 5Health News:The Quantum Group Joins Executive Committee of the Patient-Centered Primary Care Collaborative 6Health News:Orchid Cellmark Reports Improved First Quarter 2009 Financial Results 2Health News:Orchid Cellmark Reports Improved First Quarter 2009 Financial Results 3Health News:Orchid Cellmark Reports Improved First Quarter 2009 Financial Results 4Health News:Orchid Cellmark Reports Improved First Quarter 2009 Financial Results 5Health News:Orchid Cellmark Reports Improved First Quarter 2009 Financial Results 6Health News:Orchid Cellmark Reports Improved First Quarter 2009 Financial Results 7
Sensitive Eyes drops keep soft contact lenses moist....
... preservative free lubricating and rewetting ... eyes while you're wearing soft ... free formula is ideal for ... to preservatives and for frequent ...
For use to rewet and lubricate lenses during wear. Soothes and moisturizes eyes while wearing soft contact lenses....
... is the most convenient multi-purpose no rub ... bottle without the need to rub: cleans, ... removes protein build-up when used daily. Its ... a special ingredient that removes protein deposits ...
Medicine Products: